Pedro Brugarolas

Welcome to the Brugarolas lab

PEDRO BRUGAROLAS - RESEARCH - FUNDING - LAB MEMBERS - COLLABORATORS - NEWS - PUBLICATIONS - OPPORTUNITIES - CONTACT

Welcome to the laboratory of Dr. Pedro Brugarolas at the Massachusetts General Hospital and Harvard Medical School.

The focus of our group is to develop new radiopharmaceuticals for PET imaging and theranostic applications. We are particularly interested in developing and translating to humans new tracers for potassium channels to image demyelinating axons (see Developing PET tracers for K⁺ channels) and have lead the first human study with [¹⁸F]3F4AP under an FDA approved IND.

We are also interested in developing tracers for calcium channels to image neuropathic pain and epilepsy (see Developing PET tracers for Ca²⁺ channels), developing small molecules to image therapeutic monoclonal antibodies using a pretargeting approach (see PET-tag: a new approach to imaging monoclonal antibodies) and exploring new radiochemistry to make our tracers (see New fluorination and radiofluorination strategies). We also collaborate with industry in research projects related to PET (see Collaborations with Industry).

The lab is located in the historic Bulfinch building at MGH main campus only a few feet away from the MGH PET Core cyclotron which produces carbon-11 and fluorine-18 daily and the MGH animal facilities. The lab has state-of-the-art chemistry and radiochemistry equipment and access to animal and human PET scanners.

Assistant Professor of Radiology 1/2018 - present
Harvard Medical School, Boston, Massachusetts

Visiting Scientist, Radiochemistry 3/2017 - 6/2017
Mentor Victor W. Pike, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland

Postdoc, Neuroscience and PET 1/2012 - 2/2017
Mentor Brian Popko, Department of Neurology, The University of Chicago, Chicago, Illinois

Ph.D. in Chemistry 9/2006 - 12/2011
Advisor Chuan He, Department of Chemistry, The University of Chicago, Chicago, Illinois

B.E. in Computer Science 12/2008
Universidad Nacional de Educacion a Distancia - UNED, Madrid, Spain

B.S. in Chemistry 6/2005
University of Alicante, Alicante, Spain

RESEARCH SUMMARY

1. DEVELOPING PET TRACERS FOR VOLTAGE-GATED POTASSIUM CHANNELS

This work is partially funded by the NIH/NINDS, the Polsky Center for Entrepreneurship and Innovation and an MGH ECOR Physician and/or Scientist Development Award to Dr. Ramos-Torres

Potassium (K⁺) channels in myelinated axons are normally buried beneath the myelin sheath. During MS and other demyelinating conditions such as traumatic brain injury and stroke, myelin becomes damaged leaving these channels exposed, which results in leakage of intracellular K⁺ ions and disruption of axonal conduction of action potentials. Consequently, K⁺ channel blockers, such as 4-aminopyridine, have been exploited clinically to enhance axonal conduction and improve neurological function in patients with MS. We recently showed that K⁺ channels can be targeted for imaging demyelinated lesions in animal models of demyelination and are currently evaluating this tracer in humans under an IND. See ClinicalTrials.gov record for more information. We encourage anyone interested in doing human studies with [¹⁸F]3F4AP to get in touch.

2. DEVELOPING PET TRACERS FOR THE ALPHA2DELTA-1 SUBUNIT OF VOLTAGE-DEPENDENT CALCIUM CHANNELS

This work is funded by the NIH/NINDS and a K99 award from NIH/NIBIB to Dr. Zhou

Pain and seizure disorders affect millions of people worldwide. Non-invasive imaging of these conditions is critical for their diagnosis and clinical management. Current imaging methods use a combination of techniques including MRI, [¹⁸F]FDG PET and SPECT, which lack specificity. One feature shared by pain and seizure disorders is that the expression of certain calcium (Ca²⁺) channels is altered in the disease focus. As such, imaging the alpha2delta-1 subunit of voltage-dependent Ca²⁺ channels by PET may provide a new window into the pathology.

3. DEVELOPING A NON-COVALENT PRETARGETING APPROACH TO IMMUNO PET

This work is funded by the NIH/NIBIB

Therapeutic monoclonal antibodies comprise a multibilion dollar market. Just like any other therapeutic, these drugs do not work for every patient. Data from clinical trials shows responses between 15% and 60% for most therapeutic antibodies. Recent studies suggest that localization of the antibody is a good predictor of response. In this project, we are trying to develop a new way to image monoclonal antibodies using small molecule PET radioligands.

4. NEW FLUORINATION AND RADIOFLUORINATION STRATEGIES

Due to their electron-rich aromatic structure nucleophilic fluorination of pyridines is challenging, especially at the meta position. Current strategies for radiofluorination ofter require difficult to make precursors. In this project, we discovered that pyridine N-oxides which are easy to make and often commercially available can be excellent precursors. Furthermore, fluorination occurs quickly at room temperature.

5. COLLABORATIONS WITH INDUSTRY

We also have multiple collaborations with industry to radiolabel novel PET tracers and evaluate them in tissues and animal models using autoradiography and PET. If interested in collaborating with us, please get in touch!

FUNDING

Current

Can [¹⁸F]3F4AP detect brain demyelination? Evaluation of novel PET tracer in nonhuman primates and humans. 12/2019 - 11/2025
NIH/NINDS R01NS114066 (PI)

Chelators to enable theranostic alpha particle radiotherapeutic agents. 12/2023 - 11/2024
NIH/NIBIB R56EB029259
Brugarolas (subaward PI), J. Wilson, UCSB (Prime PI)

3F4AP: a new PET tracer for multiple sclerosis. 1/2018 - completion
Innovation Fund Award - Polsky Center For Entrepreneurship and Innovation at The University of Chicago
(coPI with Brian Popko)

Sensitive and specific measures of demyelination after blast overpressure brain injury. 12/2024 - 11/2026
Home Base
Brugarolas (coinvestigator), Linnman (PI)

Validation of MAO-B as a PET Biomarker of Reactive Astrogliosis in ADRD. 10/2024 - 9/2026
Alzheimer's Association
Brugarolas (coinvestigator), Serrano-Pozo (PI)

Past

Developing a PET-based method to assess myelination-promoting treatments. 7/2021 - 6/2023
Research Grant. Translational Research Program, Boston Children's Hospital
(coPI with Zhigang He)

Development of next generation α2δ-1 PET tracers for neuroimaging. 8/2022 - 3/2024
NIH/NIBIB K99EB033407
Brugarolas (Mentor), Zhou (PI)

Development of a PET radiotracer for alpha2delta-1 receptors to visualize and quantify neuropathic pain mechanisms. 10/2020 - 5/2023
NIH/NINDS R21NS120139 (PI)

Demyelination in the injured human spinal cord. 4/2020 - 3/2023
E.R. & M.J. Gordon Center for the Cure and Treatment of Paralysis
Brugarolas (coinvestigator), Linnman (PI)

New tools for imaging: diagnostics based on therapeutics. 7/2017 - 6/2022
NIH/NIBIB R00EB020075 (PI)

New tools for imaging: diagnostics based on therapeutics. 7/2015 - 6/2017
NIH/NIBIB K99EB020075 (PI)

LAB MEMBERS

Karla M. Ramos Torres, PhD Instructor
PhD in Chemistry, University of California, Berkeley, CA, 2016

Yang Sun, PhD Instructor
PhD in Chemistry, École Polytechnique Fédérale de Lausanne, Switzerland, 2019

Seresa McDowell Graduate Student
Harvard Chemistry and Chemical Biology Program

Saadi El-Saadi Undergraduate Researcher
Harvard College, Class of 2026

FORMER MEMBERS

Lauren Zhang Undergraduate Researcher, 10/2020-6/2024
Harvard College, Class of 2024

Yupeng Zhou, PhD Postdoctoral Fellow and Instructor, 9/2018-3/2024
PhD in Chemistry, Technische Universität Berline, Berlin, Germany, 2018
Currently: Assistant Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Zhongshan Institute for Drug Discovery, China

Katarina J. Makaravage, PhD Postdoctoral Fellow, 5/2019-10/2020
PhD in Chemistry, University of Michigan, Ann Arbor, MI, 2019
Currently: Staff Scientist at Syngenta, NC

Alyssa D. Bravin Undergraduate Researcher, 6/2018-6/2020
Harvard College, Class of 2020

COLLABORATORS

Eric C. Klawiter, MD
Director, Multiple Sclerosis and Neuromyelitis Optica Unit
Associate Professor, Department of Neurology, MGH

Amal Tiss, PhD
Research Fellow, Department of Radiology, MGH

Kazue Takahashi, PhD
Assistant Professor, Department of Radiology, MGH

Justin J. Wilson, PhD
Professor, Department of Chemistry, University of California, Santa Barbara

Clas Linnman, PhD
Assistant Professor, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital

Brian Popko, PhD
Professor, Department of Neurology, Northwestern University Feinberg School of Medicine

NEWS

Oct, 2024: Seresa McDowell joins the lab. Welcome, Seresa!

June, 2024: Saadi El-Saadi joins the lab and receives a Program for Research in Science and Engineering (PRISE) Award from Harvard College. Welcome, Saadi!

May, 2024: Karla's Journal of Neurochemistry paper showing that isoflurane drastically affects the metabolism of [¹⁸F]3F4AP is out is highlighted by MGH Research News [Read news]

May, 2024: Lauren graduates from Harvard and goes on to Medical School. Best wishes, Lauren!

March, 2024: Yang Sun promoted to Instructor. Congratulations, Yang!

March, 2024: Yu-Peng Zhou accepts an independent faculty position in Zhongshan Institute for Drug Discovery in China. Best wishes, Yu-Peng!

Oct., 2022: We published the results from the first human study with [¹⁸F]3F4AP in the European Journal of Nuclear Medicine and Molecular Imaging! [Read article]

Aug., 2022: Yu-Peng receives a K99 award from NIBIB to develop second generation tracers for α2δ-1. Congratulations, Yu-Peng!

July, 2022: Karla Ramos-Torres promoted to Instructor. Congratulations, Karla!

July, 2021: Pedro receives the Jordi Folch-Pi Award from The American Society for Neurochemistry.

April, 2021: Karla Ramos-Torres receives a Physician and/or Scientists Development Award from MGH ECOR. Congratulations, Karla!

Dec., 2020: We received IND and IRB approval to begin studies with [¹⁸F]3F4AP in human subjects!

Sept., 2020: Our R21 to develop a novel tracer for neuropathic pain has been selected for funding by the NIH/NINDS

March, 2019: TED-Ed video: Using radioactive drugs to see inside your body [watch video]

January, 2018: Publication of Development of a PET radioligand for potassium channels to image CNS demyelination [press coverage]

PUBLICATIONS

Preprints

36. K.M. Ramos-Torres, S. Conti, Y.P. Zhou, A. Tiss, C. Caravagna, K. Takahashi, M. He, M. Wilks, S. Eckl, K. Gong, Z. He, C. Linnman and P. Brugarolas* Imaging demyelinated axons after spinal cord injuries with PET tracer [¹⁸F]3F4AP. bioRxiv, DOI: 10.1101/2024.04.24.590984, 2024.

Journal articles

35. Y. Sun, K.M. Ramos-Torres, Y. Sun, K. Takahashi, L. Zhang, A. Tiss and P. Brugarolas*. Synthesis of K⁺ channel radioligand [¹⁸F]5-methyl-3-fluoro-4-aminopyridine and PET imaging in mice. Biorg. Med. Chem. Lett. 2024. In Press

34. T. Kanagasundaram, Y. Sun, K. Lee, S.N. MacMillan, P. Brugarolas* and J.J. Wilson*. Fluorine-18 incorporation and radiometal coordination in macropa ligands for PET imaging and targeted alpha therapy. Chem. Commun. 60, 11940-11943, 2024.

33. K.M. Ramos-Torres, Y. Sun, K. Takahashi, Y.P. Zhou and P. Brugarolas*. Common anesthetic used in preclinical PET imaging inhibits metabolism of the PET tracer [¹⁸F]3F4AP. J. Neurochem. 168(9), 2577-2586, 2024.

32. Y.P. Zhou*, L. Zhang, Y. Sun and P. Brugarolas*. Imaging of Pain using Positron Emission Tomography. iRadiology, 2(3), 339-361, 2024.

31. Y. Sun, S. Rodriguez-Rangel, L. Zhang, J.E. Sanchez-Rodriguez* and P. Brugarolas*. Chemical and biophysical characterization of novel potassium channel blocker 3-fluoro-5-methylpyridin-4-amine. Sci. Rep. 14, 11105, 2024.

30. Y.P. Zhou, M.Q. Wilks, M. Dhaynaut, N.J. Guehl, D.R. Vesper, S.H. Moon, P.A. Rice, G. El Fakhri, M.D. Normandin* and P. Brugarolas*. Radiosynthesis automation, non-human primate biodistribution and dosimetry of K⁺ channel tracer [¹¹C]3MeO4AP. EJNMMI Res. 14, 43, 2024.

29. Y.P. Zhou, M.D. Normandin, V. Belov, M.T. Macdonald-Soccorso, S.H. Moon, Y. Sun, G. El Fakhri, N.J. Guehl* and P. Brugarolas*. Evaluation of trans- and cis-4-[¹⁸F]fluorogabapentin for brain PET imaging. ACS Chem. Neurosci. 14, 23, 4208–4215, 2023.

28. Y. Sun, K.M. Ramos-Torres and P. Brugarolas*. Metabolic Stability of the Demyelination PET Tracer [¹⁸F]3F4AP and Identification of its Metabolites. J. Pharmacol. Exp. Ther. 386(1):93-101, 2023.

27. S. Telu*, S. Jana, M.B. Haskali, B.Y. Yang, J. Jakobsson, Q. Zhao, K.M. Ramos-Torres, P. Brugarolas and V.W Pike* Broad-scope syntheses of [¹¹C/[¹¹F] trifluoromethylarenes from aryl(mesityl)iodonium salts. Chem. Eur. J. 29, e202204004. 2023.

26. P. Brugarolas*, M.Q. Wilks, J. Noel, J.A. Kaiser, D.R. Vesper, K.M. Ramos-Torres, N.J. Guehl, M.T. Macdonald-Soccorso, Y. Sun, P.A. Rice, D.L. Yokell, R. Lim, M.D. Normandin and G. El Fakhri*. Human biodistribution and radiation dosimetry of the demyelination tracer [¹⁸F]3F4AP. Eur. J. Nuc. Med. Mol. Imag. 50, 344-51, 2023.

25. Y. Sun, N.J. Guehl, Y.P. Zhou, V. Belov, K. Takahashi, M. Dhaynaut, S.H. Moon, G. El Fakhri, M.D. Normandin and P. Brugarolas*. Radiochemical Synthesis and Evaluation of 3-[¹¹C]methyl-4-aminopyridine in Rodents and Non-Human Primates for Imaging Potassium Channels in the CNS. ACS Chem. Neurosci. 13, 23, 3342-51, 2022.

24. Y.P. Zhou, Y. Sun, K. Takahashi, V. Belov, N. Andrews, C.J. Woolf and P. Brugarolas*. Development of a PET radioligand for α2δ-1 subunit of calcium channels for imaging neuropathic pain. Eur. J. Med. Chem. 242:114688, 2022.

23. F.J. Detmer, N.M. Alpert, S.H. Moon, M. Dhaynaut, J.L. Guerrero, N.J. Guehl, F. Xing,P. Brugarolas, T.M. Shoup, M.D. Normandin, M. Pelletier-Galarneau, G. El Fakhri* and Y. Petibon*. PET imaging of mitochondrial function in acute doxorubicin-induced cardiotoxicity: a proof-of-principle study. Sci. Rep. 12:6122, 2022.

22. Y.P. Zhou, K.J. Makaravage and P. Brugarolas*. Radiolabeling with [¹¹C]HCN for positron emission tomography. Nuc. Med. Biol. 102-3:56-86, 2021.

21. N.J. Guehl, R. Neelamegam, Y. Zhou, S.H. Moon, M. Dhaynaut, G. El Fakhri, M.D. Normandin* and P. Brugarolas*. Radiochemical Synthesis and Evaluation in Nonhuman Primates of 3-[¹¹C]methoxy-4-aminopyridine: a novel PET tracer for Imaging Potassium Channels in the CNS. ACS Chem. Neurosci. 12(4):756-765, 2021.

20. T.M. Shoup, A. Griciuc, M.D. Normandin, L. Quinti, L.V. Walsh, M. Dhaynaut, S. Moon, N.J. Guehl, P. Brugarolas, D.R. Elmaleh*, G. El Fakhri* and R.E. Tanzi. Evaluation of Fluorinated Cromolyn Derivatives as Potential Therapeutics for Alzheimer’s Disease. J. Alzheimer's Dis. 80(2):775-786, 2021.

19. N.J. Guehl, K.M. Ramos-Torres, C. Linnman, S. Moon, M. Dhaynaut, M.Q. Wilks, P.K. Han, C. Ma, R. Neelamegam, Y. Zhou, B. Popko, J.A. Correia, D.S. Reich, G. El Fakhri, P. Herscovitch, M.D. Normandin* and P. Brugarolas*. Evaluation of the potassium channel tracer [¹⁸F]3F4AP in rhesus macaques. J. Cereb. Blood Flow Metab. 41(7):1721-1733, 2021.

18. K.M. Ramos-Torres, Y. Zhou, B. Yang, N.J. Guehl, S. Moon, S. Telu, M.D. Normandin, V.W Pike* and P Brugarolas*. Syntheses of [¹¹C]2- and [¹¹C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for demyelinating diseases. RSC Med. Chem. 11, 1161-1167, 2020.

17. S. Foxley*, G. Wildenberg, V. Sampathkumar, G.S. Karczmar, P. Brugarolas and N. Kasthuri. Sensitivity to myelin using model-free analysis of the water resonance line-shape in postmortem mouse brain. Magn. Reson. Imaging 85: 667–677, 2020.

16. P. Brugarolas, J. Comstock, D.W. Dick, T. Ellmer, J.W. Engle, S.E. Lapi, S.H. Liang, E.E. Parent, N.V.K. Pillarsetty, S. Selivanova, X. Sun, A. Vavere and P.J.H. Scott*, SNMMI RPSC Council. Fifty Years of Radiopharmaceuticals. J. Nucl. Med. Technol. 48(Suppl 1), 34S-39S, 2020.

15. S. Rodríguez-Rangel, A.D. Bravin, K.M.Ramos-Torres, P. Brugarolas* and J.E. Sánchez-Rodríguez* Structure-activity relationship studies of four novel 4-aminopyridine K⁺ channel blockers. Sci. Rep. 10(1), 52, 2020.

14. P. Brugarolas*, D.S. Reich and B. Popko. Detecting Demyelination by PET: The Lesion as Imaging Target. Mol. Imaging, 17:1536012118785471, 2018.

13. B. Elbaz, J.D. Aaker, S. Isaac, A. Kolarzyk, P. Brugarolas, A. Eden and B. Popko* Phosphorylation State of ZFP24 Controls Oligodendrocyte Differentiation. Cell Rep. 23(8), 2254-2263, 2018

12. P. Brugarolas*, J.E. Sánchez-Rodríguez, H.M. Tsai, F. Basuli, S.H. Cheng, X. Zhang, A.V. Caprariello, J. Lacroix, R. Freifelder, D. Murali, O. DeJesus, R.H. Miller, R.E. Swenson, C.T. Chen, P. Herscovitch, D.S. Reich, F. Bezanilla and B. Popko.* Development of a PET radioligand for potassium channels to image CNS demyelination. Sci. Rep. 8, 607, 2018.

11. F. Basuli*, X. Zhang, P. Brugarolas, D.S. Reich and R.E. Swenson. An efficient new method for the synthesis of [¹⁸F]3-fluoro-4-aminopyridine via Yamada-Curtius rearrangement. J. Labelled. Comp. Radiopharm. 61(2):112-117, 2018.

10. P. Brugarolas*, M. Bhuiyan, A. Kucharski and R. Freifelder. Automated radiochemical synthesis of [¹⁸F]3F4AP: a novel PET tracer for imaging demyelinating diseases. J. Vis. Exp. (123): 55537, 2016.

9. P. Brugarolas*, R. Freifelder, S.H. Cheng and O. DeJesus. Synthesis of meta-substituted [¹⁸F]3-fluoro-4-aminopyridine via direct radiofluorination of pyridine N-oxides. Chem. Commun. 52, 7150-2, 2016.

8. S. Way, J. Podojil, B. Clayton, A. Zaremba, T. Collins, R. Kunjamma, A. Robinson, P. Brugarolas, R. Miller, S. Miller and B. Popko*. Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nat. Commun. 6, 6532, 2015.

7. P. Brugarolas and B. Popko*. Remyelination therapy goes to trial for multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 1(2):e26, 2014.

6. Q. Ji, L. Zhang, M.B. Jones, F. Sun, X. Deng, H. Liang, H. Cho, P. Brugarolas, Y.N. Gao, S.N. Peterson, L. Lan, T. Bae and C. He*. Molecular mechanism of quinone signaling mediated through S-quinonization of a YodB family repressor QsrR. Proc. Natl. Acad. Sci. U. S. A. 110(13):5010-5, 2013.

5. P. Brugarolas, F. Movahedzadeh, Y. Wang, N. Zhang, I.L. Bartek, Y.N. Gao, M.I. Voskuil, S.G. Franzblau and C. He*. The oxidation-sensing regulator (MosR) is a new redox-dependent transcription factor in Mycobacterium tuberculosis. J. Biol. Chem. 287(45):37703-12, 2012.

4. B.P. Aryal, P. Brugarolas and C. He*. Binding of ReO₄ with an engineered MoO₄-binding protein: towards a new approach in radiopharmaceutical applications. J. Biol. Inorg. Chem. 17(1):97-106, 2012.

3. P. Brugarolas, E.M. Duguid, W. Zhang, C.B. Poor and C. He*. Structural and biochemical characterization of N5-carboxyaminoimidazole ribonucleotide synthetase and N5-carboxyaminoimidazole ribonucleotide mutase from Staphylococcus aureus. Acta Crystallogr. D Biol. Crystallogr. 67(8):707-15, 2011.

2. P.R. Chen, P. Brugarolas and C. He*. Redox signaling in human pathogens. Antioxid. Redox Signal. 14(6):1107-18, 2011.

1. J. García-Martínez*, P. Brugarolas and S. Domínguez-Domínguez. Ordered circular mesoporosity induced by phospholipids. Micropor. Mesopor. Materials. 100(1-3): 63-69, 2007.

PATENTS

3. U.S. Patent Application: PCT/US2021/028455. Fluorinated derivatives of gabapentin and methods of use thereof. Inventor: P. Brugarolas, Y. Zhou. Priority date 4/2020. Patent Pending. [Patentscope]

2. U.S. Patent: US10160695B2. Synthesis of meta-substituted [¹⁸F]3-fluoro-4-aminopyridines by direct radiofluorination of pyridine N-oxides. Inventor: P. Brugarolas. Priority date 4/2016. [GooglePatents]

1. U.S. Patents: US9617215B2 and US10442767B2. Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging. Inventors: P. Brugarolas, B. Popko, D. Appelbaum, C.T. Chen. Priority date 5/2012. Licensed by Fuzionaire Diagnostics Dec. 2020. [GooglePatents] [GooglePatents2]

INVITED TALKS

3/2024 "Development of radiolabeled 4-aminopyridine derivatives for imaging demyelination and neurodegeneration in the CNS and PNS.” Section on PET Radiopharmaceuticals, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.

6/2023 "Making new PET tracers for brain imaging through novel radiochemistry.” Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, Stanford, CA.

12/2022 "Development of PET radioligands for multiple sclerosis and other diseases.” Radiology Grand Rounds, University of Rochester School of Medicine, Rochester, NY.

11/2022 "Making new PET tracers for brain imaging and developing new (radio)chemistry along the way.” Bilkent Chemistry Seminar Series, Chemistry Department, Bilkent University, Ankara, Turkey.

10/2022 "Development and evaluation of novel PET tracers for neurological diseases.” Global R&D Seminar, GE Healthcare.

11/2021 "Development of PET radioligands for multiple sclerosis and other diseases.” Department of Nuclear Medicine, Clínica Universitaria de Navarra, Pamplona, Spain.

5/2021 "Development of PET radioligands for multiple sclerosis and other diseases.” Department of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden.

10/2020 "Development and translation of [¹⁸F]3F4AP: a novel PET tracer for demyelinating diseases.” Department of Radiology, Brigham and Women’s Hospital, Boston, MA.

4/2020 "Developing PET radiotracers for visualizing brain demyelination and other pathological processes”. Department of Radiology, Weill Cornell Medicine, New York, NY.

1/2020 "Developing PET Radiotracers for Brain Injuries, Pain and Other Diseases”. Department of Radiology, The University of Chicago, Chicago, IL.

OPPORTUNITIES

Student and Postdoc Opportunties Available!
Please email Dr. Brugarolas with CV, letter describing research background and interests, and contact info of three references.

CONTACT INFORMATION

Pedro Brugarolas, PhD
Assistant Professor
Department of Radiology, Harvard Medical School
55 Fruit St., Bulfinch 051
Boston, MA 02114

Tel. (617) 643-4574
E-mail: pbrugarolas AT mgh DOT harvard DOT edu

Updated 10/18/2024